Abbott posts 2024 medical device sales gains following structural heart, CGM launches
For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve repair implant and FDA clearances for two over-the-counter blood sugar trackers, among other products.
Hosted on MSN23m
Abbott Laboratories Will Outperform Healthcare Stocks in 2025The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...
Abbott Laboratories is forecasting lower-than-expected first-quarter earnings but full-year profit in line with Wall Street ...
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device that helps people ...
(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback